# A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

> **NCT00158860** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 384 (actual)

## Conditions studied

- Herpes Genitalis

## Interventions

- **DRUG:** Valaciclovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00158860
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-21
- **Primary completion:** 2006-07-26
- **Final completion:** 2006-07-26
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00158860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00158860, "A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00158860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*